inclusion criteria: 1. 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. 7. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. 7. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. outpatient setting age ≥ 18 years and ≤ 80 years at the time of the assessment able and willing to understand the study, adhere to all study procedures, and provide written informed consent initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. outpatient setting age ≥ 18 years and ≤ 80 years at the time of the assessment able and willing to understand the study, adhere to all study procedures, and provide written informed consent initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. 7. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. 7. other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. outpatient setting. 2. age ≥ 18 years and ≤ 80 years at the time of the assessment. 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent. 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. outpatient setting. 2. age ≥ 18 years and ≤ 80 years at the time of the assessment. 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent. 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. 5. at baseline, at least two symptoms should have mild or higher severity score, where at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste or at least one symptom has a moderate or higher severity score on the covid outpatient symptom scale (coss). 6. participant's covid-19 related symptom onset occurred within 7 days prior to time of randomization. additional inclusion criteria for camostat protocol: 1. if male, must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication 2. if female, must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication, and must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy.

inclusion criteria: 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. we rely on stanford's assay, which was issued an emergency use authorization (eua number is eua200036). 5. at baseline, at least two symptoms should have moderate or higher severity score on the covid outpatient symptom scale (coss) 6. additional inclusion criteria may pertain to specific drugs as described in study specific protocols.

inclusion criteria: 1. outpatient setting 2. age ≥ 18 years and ≤ 80 years at the time of the assessment 3. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 4. initial diagnosis of covid-19 disease as defined by an fda-cleared molecular diagnostic assay positive for sars-cov-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent. we rely on stanford's assay, which was issued an emergency use authorization (eua number is eua200036). 5. at baseline, at least two symptoms should have moderate or higher severity score on the covid outpatient symptom scale (coss) 6. additional inclusion criteria may pertain to specific drugs as described in study specific protocols.